<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131885</url>
  </required_header>
  <id_info>
    <org_study_id>13430</org_study_id>
    <secondary_id>R21AT002297</secondary_id>
    <nct_id>NCT00131885</nct_id>
  </id_info>
  <brief_title>Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel</brief_title>
  <official_title>Effects of St. John's Wort on Levonorgestrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effects of St. John's wort, a common herbal remedy, on
      metabolism of the female contraceptive hormone levonorgestrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, St. John's wort has become one of the most commonly used botanicals.
      Levonorgestrel is a form of progesterone, a female hormone involved in conception. It can be
      given as both a pill and an injection and is used for contraception and for the treatment of
      endometriosis. However, evidence suggests that St. John's wort may reduce the effectiveness
      of the contraceptive hormone levonorgestrel. This study will determine whether interactions
      between St. John's wort and levonorgestrel reduce the effectiveness of the hormone. This
      study will also determine whether a higher dose of levonorgestrel will override the effects
      of St. John's wort.

      All participants will receive a single dose of levonorgestrel between Days 9 and 12 of their
      first menstrual cycle after entering this study. Blood and urine collection will occur
      immediately after the levonorgestrel is given and every week until participants' next
      menstrual cycle to determine the levels of reproductive hormones in participants' bodies.

      At the beginning of participants' next menstrual cycle, they will be randomly assigned to one
      of four groups and receive either St. John's wort or placebo for 6 weeks. Group 1 will
      receive a placebo; Groups 2 and 3 will receive a standard dose of St. John's wort (900 mg per
      day); and Group 4 will receive an increased dose of St. John's wort (1500 mg per day). After
      6 weeks, Groups 1, 2, and 4 will receive 150 mcg levonorgestrel; and Group 3 will receive 225
      mcg levonorgestrel. Blood and urine collection will occur immediately after levonorgestrel is
      given and every week until participants' next menstrual cycle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve for 0 to 24 Hours After Drug Administration, Done Between Days 9 and 12 of the Menstrual Cycle at Time 1 (Before) and Time 2 (During Treatment With St. John's Wort or Placebo)</measure>
    <time_frame>Area Under the Concentration versus Time curve for 0 to 24 hours after drug administration, between Days 9 and 12 of the menstrual cycle, done at Time 1 and at Time 2</time_frame>
    <description>Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo). Serum samples drawn at 0, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, and 24 hours, following oral administration of a dose of levonorgestrel.
Treatment between the two time periods was with St. John's Wort or placebo herb, beginning after the Time 1 (baseline) and continued for 5 weeks until Time 2.
Estimates of levonorgestrel clearance were made using a two stage non-compartmental approach to determine individual and group parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Progesterone Levels Above 3.0 ng/ml at Time 1 (Baseline) and Time 2 (After Intervention With St John's Wort or Placebo).</measure>
    <time_frame>Progesterone levels drawn at weekly intervals after dosing with levonorgestrel between Days 9 and 12 of the menstrual cycle, at each time point until menses</time_frame>
    <description>Serum progesterone levels were drawn at the time of dosing with levonorgestrel and then at weekly intervals until menses occurred. This was done at Time 1 (baseline), and again at Time 2 (after 5 weeks of dosing with St. John's Wort or placebo).
Possible ovulation was defined as a serum progesterone &gt;3ng/ml within 2 weeks of Days 9-12 of the menstrual cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (L/hr) of Levonorgestrel Over 24 Hours for Each Dosage Group and Each Study Session.</measure>
    <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
    <description>Average and standard deviation for Clearance (L/hr) of Levonorgestrel study for each dosage group and each study session.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Follicle-stimulating Hormone Drawn at Weekly Intervals Until Next Menses</measure>
    <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
    <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Estradiol-17b (E2) Drawn at Weekly Intervals Until Next Menses</measure>
    <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
    <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Luteinizing Hormone, Drawn at Weekly Intervals Until Next Menses</measure>
    <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
    <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel 1.5 with Placebo Herb</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a placebo herb daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel 1.5 with SJW 900 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took St. John's Wort (SJW) 900 mg a Day orally for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel 2.25 with SJW 900 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules three times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 2.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel 1.5 with SJW 1500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules five times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Control (Placebo Herb)</intervention_name>
    <description>Placebo herb three times daily (ground cellulose) for 4-6 weeks</description>
    <arm_group_label>Levonorgestrel 1.5 with Placebo Herb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>St. John's Wort</intervention_name>
    <description>St. John's Wort (Hypericum perforatum) orally or 4-6 weeks</description>
    <arm_group_label>Levonorgestrel 1.5 with SJW 900 mg</arm_group_label>
    <arm_group_label>Levonorgestrel 2.25 with SJW 900 mg</arm_group_label>
    <arm_group_label>Levonorgestrel 1.5 with SJW 1500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel</intervention_name>
    <description>Levonorgestrel in a single oral dose</description>
    <arm_group_label>Levonorgestrel 1.5 with Placebo Herb</arm_group_label>
    <arm_group_label>Levonorgestrel 1.5 with SJW 900 mg</arm_group_label>
    <arm_group_label>Levonorgestrel 2.25 with SJW 900 mg</arm_group_label>
    <arm_group_label>Levonorgestrel 1.5 with SJW 1500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 20 and 25

          -  Regular menstrual cycles for at least 3 months prior to study entry

        Exclusion Criteria:

          -  Current use of foods, herbs, vitamins, over-the-counter supplements, or any
             medications that could alter pharmacokinetics of other drugs

          -  Medical contraindications to the use of contraceptives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia A. Murphy, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>College of Nursing, University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005 Jun;71(6):402-8.</citation>
    <PMID>15914127</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2005</study_first_submitted>
  <study_first_submitted_qc>August 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2005</study_first_posted>
  <results_first_submitted>March 21, 2010</results_first_submitted>
  <results_first_submitted_qc>May 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2010</results_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Patricia Murphy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Menstruation</keyword>
  <keyword>Complementary Therapies</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Hypericum</keyword>
  <keyword>St. John's wort</keyword>
  <keyword>Levonorgestrel</keyword>
  <keyword>Women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible participants were recruited via local advertising.</recruitment_details>
      <pre_assignment_details>No enrolled participants were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
          <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="P2">
          <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
          <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="P3">
          <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
          <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="P4">
          <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
          <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Time 1: First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Time 2: Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
          <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="B2">
          <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
          <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="B3">
          <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
          <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="B4">
          <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
          <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.1" spread="3.6"/>
                    <measurement group_id="B2" value="22.4" spread="3.1"/>
                    <measurement group_id="B3" value="23" spread="3.5"/>
                    <measurement group_id="B4" value="22.9" spread="3.4"/>
                    <measurement group_id="B5" value="22.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve for 0 to 24 Hours After Drug Administration, Done Between Days 9 and 12 of the Menstrual Cycle at Time 1 (Before) and Time 2 (During Treatment With St. John's Wort or Placebo)</title>
        <description>Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo). Serum samples drawn at 0, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, and 24 hours, following oral administration of a dose of levonorgestrel.
Treatment between the two time periods was with St. John's Wort or placebo herb, beginning after the Time 1 (baseline) and continued for 5 weeks until Time 2.
Estimates of levonorgestrel clearance were made using a two stage non-compartmental approach to determine individual and group parameters.</description>
        <time_frame>Area Under the Concentration versus Time curve for 0 to 24 hours after drug administration, between Days 9 and 12 of the menstrual cycle, done at Time 1 and at Time 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
            <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O2">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
            <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O3">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
            <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O4">
            <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
            <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve for 0 to 24 Hours After Drug Administration, Done Between Days 9 and 12 of the Menstrual Cycle at Time 1 (Before) and Time 2 (During Treatment With St. John's Wort or Placebo)</title>
          <description>Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo). Serum samples drawn at 0, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, and 24 hours, following oral administration of a dose of levonorgestrel.
Treatment between the two time periods was with St. John's Wort or placebo herb, beginning after the Time 1 (baseline) and continued for 5 weeks until Time 2.
Estimates of levonorgestrel clearance were made using a two stage non-compartmental approach to determine individual and group parameters.</description>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-24 hours after drug administration Time 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.3" spread="530.6"/>
                    <measurement group_id="O2" value="379.4" spread="201.3"/>
                    <measurement group_id="O3" value="339.4" spread="201.2"/>
                    <measurement group_id="O4" value="253.3" spread="114.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-24 hours after drug administration Time 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478.2" spread="374.0"/>
                    <measurement group_id="O2" value="317.4" spread="171.6"/>
                    <measurement group_id="O3" value="439.4" spread="320.1"/>
                    <measurement group_id="O4" value="210.1" spread="100.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progesterone Levels Above 3.0 ng/ml at Time 1 (Baseline) and Time 2 (After Intervention With St John's Wort or Placebo).</title>
        <description>Serum progesterone levels were drawn at the time of dosing with levonorgestrel and then at weekly intervals until menses occurred. This was done at Time 1 (baseline), and again at Time 2 (after 5 weeks of dosing with St. John's Wort or placebo).
Possible ovulation was defined as a serum progesterone &gt;3ng/ml within 2 weeks of Days 9-12 of the menstrual cycle.</description>
        <time_frame>Progesterone levels drawn at weekly intervals after dosing with levonorgestrel between Days 9 and 12 of the menstrual cycle, at each time point until menses</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
            <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O2">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
            <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O3">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
            <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O4">
            <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
            <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progesterone Levels Above 3.0 ng/ml at Time 1 (Baseline) and Time 2 (After Intervention With St John's Wort or Placebo).</title>
          <description>Serum progesterone levels were drawn at the time of dosing with levonorgestrel and then at weekly intervals until menses occurred. This was done at Time 1 (baseline), and again at Time 2 (after 5 weeks of dosing with St. John's Wort or placebo).
Possible ovulation was defined as a serum progesterone &gt;3ng/ml within 2 weeks of Days 9-12 of the menstrual cycle.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ovulation (Progesterone Levels &gt; 3.0 ng/ml) Time 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovulation (Progesterone Levels &gt;3.0 ng/ml) Time 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Levels of Follicle-stimulating Hormone Drawn at Weekly Intervals Until Next Menses</title>
        <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
        <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
            <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O2">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
            <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O3">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
            <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O4">
            <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
            <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Levels of Follicle-stimulating Hormone Drawn at Weekly Intervals Until Next Menses</title>
          <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FSH, IU/mL, Time 1, week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="5.7"/>
                    <measurement group_id="O2" value="14.0" spread="4.8"/>
                    <measurement group_id="O3" value="15.8" spread="8.0"/>
                    <measurement group_id="O4" value="13.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH, IU/mL, Time 1, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="5.0"/>
                    <measurement group_id="O2" value="14.7" spread="4.8"/>
                    <measurement group_id="O3" value="13.9" spread="5.2"/>
                    <measurement group_id="O4" value="13.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH, IU/mL, Time 1, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="4.2"/>
                    <measurement group_id="O2" value="13.4" spread="4.3"/>
                    <measurement group_id="O3" value="20.4" spread="12.0"/>
                    <measurement group_id="O4" value="15.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH, IU/mL, Time 2, week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="3.5"/>
                    <measurement group_id="O2" value="13.0" spread="3.6"/>
                    <measurement group_id="O3" value="17.5" spread="10.1"/>
                    <measurement group_id="O4" value="14.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH, IU/mL, Time 2, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="3.0"/>
                    <measurement group_id="O2" value="15.9" spread="5.0"/>
                    <measurement group_id="O3" value="17.7" spread="8.8"/>
                    <measurement group_id="O4" value="13.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH, IU/mL, Time 2, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="4.4"/>
                    <measurement group_id="O2" value="14.1" spread="4.5"/>
                    <measurement group_id="O3" value="14.8" spread="4.7"/>
                    <measurement group_id="O4" value="16.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance (L/hr) of Levonorgestrel Over 24 Hours for Each Dosage Group and Each Study Session.</title>
        <description>Average and standard deviation for Clearance (L/hr) of Levonorgestrel study for each dosage group and each study session.</description>
        <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
            <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O2">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
            <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O3">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
            <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O4">
            <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
            <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (L/hr) of Levonorgestrel Over 24 Hours for Each Dosage Group and Each Study Session.</title>
          <description>Average and standard deviation for Clearance (L/hr) of Levonorgestrel study for each dosage group and each study session.</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance (L/hr) Time 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="2.60"/>
                    <measurement group_id="O2" value="4.93" spread="2.19"/>
                    <measurement group_id="O3" value="6.39" spread="4.23"/>
                    <measurement group_id="O4" value="6.85" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance L/hr Time 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="2.44"/>
                    <measurement group_id="O2" value="5.63" spread="2.08"/>
                    <measurement group_id="O3" value="7.68" spread="4.97"/>
                    <measurement group_id="O4" value="8.92" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Levels of Estradiol-17b (E2) Drawn at Weekly Intervals Until Next Menses</title>
        <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
        <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
            <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O2">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
            <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O3">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
            <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O4">
            <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
            <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Levels of Estradiol-17b (E2) Drawn at Weekly Intervals Until Next Menses</title>
          <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Estradiol, pg/mL, Time 1, week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.3" spread="64.3"/>
                    <measurement group_id="O2" value="137.2" spread="76.9"/>
                    <measurement group_id="O3" value="131.1" spread="75.0"/>
                    <measurement group_id="O4" value="103.5" spread="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol, pg/mL, Time 1, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.2" spread="90.0"/>
                    <measurement group_id="O2" value="154.7" spread="117.1"/>
                    <measurement group_id="O3" value="138.4" spread="77.7"/>
                    <measurement group_id="O4" value="290.6" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol, pg/mL,Time 1, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.4" spread="103.9"/>
                    <measurement group_id="O2" value="107.9" spread="39.3"/>
                    <measurement group_id="O3" value="132.6" spread="73.3"/>
                    <measurement group_id="O4" value="230.4" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol, pg/mL,Time 2, week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.2" spread="73.9"/>
                    <measurement group_id="O2" value="102.0" spread="44.2"/>
                    <measurement group_id="O3" value="119.3" spread="77.9"/>
                    <measurement group_id="O4" value="123.4" spread="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol, pg/mL,Time 2, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.7" spread="227.1"/>
                    <measurement group_id="O2" value="121.6" spread="57.5"/>
                    <measurement group_id="O3" value="113.9" spread="71.1"/>
                    <measurement group_id="O4" value="118.0" spread="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estradiol, pg/mL,Time 2, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.3" spread="80.5"/>
                    <measurement group_id="O2" value="192.0" spread="101.2"/>
                    <measurement group_id="O3" value="102.9" spread="75.1"/>
                    <measurement group_id="O4" value="108.7" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Levels of Luteinizing Hormone, Drawn at Weekly Intervals Until Next Menses</title>
        <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
        <time_frame>Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
            <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O2">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
            <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O3">
            <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
            <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
          </group>
          <group group_id="O4">
            <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
            <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Levels of Luteinizing Hormone, Drawn at Weekly Intervals Until Next Menses</title>
          <description>Descriptive reporting of secondary outcomes of reproductive hormone levels (including FSH, E2, LH).
Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo).
Weekly means are reported for both time periods at week 0 (day of pharmacokinetic study), week 1 (one week after pharmacokinetic study) and week 2 (2 weeks after pharmacokinetic study).</description>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LH, IU/L, Time 1, week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="10.1"/>
                    <measurement group_id="O2" value="20.9" spread="10.4"/>
                    <measurement group_id="O3" value="26.4" spread="15.7"/>
                    <measurement group_id="O4" value="25.3" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH, IU/L, Time 1, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="16.1"/>
                    <measurement group_id="O2" value="30.2" spread="21.8"/>
                    <measurement group_id="O3" value="24.6" spread="16.3"/>
                    <measurement group_id="O4" value="25.3" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH, IU/L, Time 1, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="20.1"/>
                    <measurement group_id="O2" value="23.1" spread="14.7"/>
                    <measurement group_id="O3" value="25.6" spread="22.1"/>
                    <measurement group_id="O4" value="23.2" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH IU/L, Time 2, week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="16.5"/>
                    <measurement group_id="O2" value="28.4" spread="14.9"/>
                    <measurement group_id="O3" value="31.9" spread="27.5"/>
                    <measurement group_id="O4" value="46.3" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH, IU/L, Time 2, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="20.0"/>
                    <measurement group_id="O2" value="27.5" spread="17.9"/>
                    <measurement group_id="O3" value="40.0" spread="46.5"/>
                    <measurement group_id="O4" value="28.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH, IU/L, Time 2, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="22.5"/>
                    <measurement group_id="O2" value="27.7" spread="19.1"/>
                    <measurement group_id="O3" value="27.7" spread="19.1"/>
                    <measurement group_id="O4" value="39.1" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg</title>
          <description>Group 1: one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by placebo herb and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="E2">
          <title>LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg</title>
          <description>Group 2: One-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day, and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="E3">
          <title>LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose</title>
          <description>Group 3: A one-time oral dose of levonorgestrel 1.5 mg mg at the first pharmacokinetic study, followed by St. John’s Wort 300 mg orally three times per day (900 mg total) and a one-time oral dose of levonorgestrel 2.25 mg at the second pharmacokinetic study</description>
        </group>
        <group group_id="E4">
          <title>LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG</title>
          <description>Group 4: A one-time oral dose of levonorgestrel 1.5 mg at the first pharmacokinetic study, then St. John’s Wort 300 mg orally five times per day (total 1500 mg daily) and a one-time oral dose of levonorgestrel 1.5 mg at the second pharmacokinetic study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Patricia Murphy, DrPH</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-793-5729</phone>
      <email>patricia.murphy@nurs.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

